Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Xenofon Baraliakos, MD, PhD

Professor for Internal Medicine and Rheumatology
Ruhr-University Bochum
Bochum, Germany

Disclosures

Xenofon Baraliakos, MD, PhD, has no relevant financial relationships.

Atul Deodhar, MD

Professor of Medicine
Medical Director of Rheumatology Clinics
Oregon Health & Science University
Portland, Oregon, United States

Disclosures

Atul Deodhar, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Amgen; Aurinia; Bristol Myers Squibb; Celgene; Eli Lilly; GlaxoSmithKline; Janssen; MoonLake; Novartis; Pfizer; UCB
Speaker or member of speakers bureau for: Janssen; Novartis; Pfizer; UCB
Research funding from: AbbVie; Bristol Myers Squibb; Celgene; Eli Lilly; GlaxoSmithKline; Novartis; Pfizer; UCB

Denis Poddubnyy, MD, PhD

Professor of Medicine
Head of Rheumatology
Division of Gastroenterology, Infectious Diseases, and Rheumatology
Charité - Universitätsmedizin Berlin
Berlin, Germany

Disclosures

Denis Poddubnyy, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Biocad; Eli Lilly; Galapagos; Gilead; GlaxoSmithKline; Janssen; Merck Sharp & Dohme; MoonLake; Novartis; Pfizer; Sansung Bioepis; UCB
Speaker or member of speakers bureau for: AbbVie; Bristol Myers Squibb; Eli Lilly; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; UCB
Research funding from: AbbVie; Eli Lilly; Merck Sharp & Dohme; Novartis; Pfizer

Editor

Marinella Calle, PhD, CMPP

Senior Medical Education Director, WebMD Global, LLC

Disclosures

Marinella Calle, PhD, CMPP, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

From Medscape Education

Clinical Decision Making in Axial Spondyloarthritis: A Patient Journey From Diagnosis to Management

Authors: Xenofon Baraliakos, MD, PhD; Atul Deodhar, MD; Denis Poddubnyy, MD, PhDFaculty and Disclosures

processing....

Posted: 11/10/2022

This activity is intended for an international audience of rheumatologists, radiologists, and primary care physicians.

The goal of this activity is for learners to be better able to assess the key signs and symptoms of axSpA and optimize the therapeutic management of patients with this condition.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Treatment goals for the management of patients with axSpA
- Impact of currently approved therapies on spinal radiographic progression
Have greater competence related to the
- Diagnosis and assessment of axSpA

Educational Impact Challenge

The goal of this activity is for learners to be better able to assess the key signs and symptoms of axSpA and optimize the therapeutic management of patients with this condition.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 7

Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of WebMD Global, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Xenofon Baraliakos, MD, PhD

Atul Deodhar, MD

Denis Poddubnyy, MD, PhD

Editor

Marinella Calle, PhD, CMPP

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Clinical Decision Making in Axial Spondyloarthritis: A Patient Journey From Diagnosis to Management

Educational Impact Challenge